News - Eisai

Filter

Current filters:

Eisai

Popular Filters

46 to 70 of 114 results

Eisai joins trend to enter Russian pharma market, with Halaven launch

26-03-2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

08-03-2013

The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai/Morphotek's farletuzumab fails on ovarian cancer Ph III trial

14-01-2013

USA-based Morphotek, a wholly-owned subsidiary of Japanese drug major Eisai (TYO: 4523) which acquired…

BiotechnologyEisaifarletuzumabMorphotekOncologyPharmaceuticalResearch

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Eisai in neurological disease discovery alliance with UCL

13-12-2012

Japanese pharmaceutical major Eisai (TYO: 4523) and University College London, UK, yesterday revealed…

EisaiNeurologicalPharmaceuticalResearch

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

25-11-2012

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease…

AriceptEbixaEisaiEuropeExelon PatchLundbeckMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalResearch

FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR

23-10-2012

The US Food and Drug Administration yesterday approved Japanese drug major Eisai's (TYO: 4523) Fycompa…

EisaiFycompaNeurologicalNorth AmericaOxtellar XRPharmaceuticalRegulationSupernus Pharmaceuticals

Santen in ophthalmics deal with Eisai; Sets up new company in China

26-09-2012

Japan's Santen Pharmaceutical (TYO: 4536) has entered into an option agreement with drug major Eisai…

Asia-PacificEisaiLicensingMarkets & MarketingOphthalmicsPharmaceuticalSanten Pharmaceuticals

Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst

13-09-2012

Japanese drug major Eisai (TYO: 4523) has announced the first European launch today of Fycompa (perampanel),…

EisaiFycompaMarkets & MarketingNeurologicalPharmaceuticalResearchTropical diseasesVaccines

Public Citizen sues FDA for failing to ban dangerous dose of Aricept

07-09-2012

The Food and Drug Administration has dragged its feet for too long on a petition calling on the agency…

AriceptEisaiLegalNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Eisai gets South Korean approval for breast cancer drug Halaven

04-09-2012

The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from…

Asia-PacificEisaiHalavenOncologyPharmaceuticalRegulation

Positive final pivotal Ph III results for Eisai's Fycompa

21-08-2012

Results from the final pivotal Phase III study and long term Phase III extension study of Japanese drug…

EisaiFycompaNeurologicalPharmaceuticalResearch

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30-07-2012

Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Eisai's Fycompa improves seizure control, pivotal Ph III study shows

27-07-2012

Japanese drug major Eisai (TYO: 4523) announced results from a pivotal Phase III clinical trial (Study…

EisaiFycompaNeurologicalperampanelPharmaceuticalResearch

46 to 70 of 114 results

Back to top